. Values of parameters in the model.
Text S1. Parameter calibration
Biological descriptions and values of the model parameters are listed in Table S1 . Most of the parameters involved in the cellular dynamics and pharmacokinetics modules were collected from previous studies [1] [2] [3] , while other parameters were calibrated according to recent experimental [4, 5] and clinical data [6] . We provide details regarding the calibration of the parameter values below.
Parameters involved in DIRF secretion. Recent studies [4] (extended data, Figure 4d in Ref. [4] ) have reported that the levels of some murine stroma-derived cytokines, such as HGF, IGF, MFGE8 and TREM1, were upregulated by 1.6-to 10-fold in response to treatment with Vemurafenib (a BRAF inhibitor) compared to vehicle treatment. The newly secreted DIRFs are described in equation (7) in the main text.
The DIRF basal level was assumed to be 0.1. To ensure that the change in total DIRF (basal plus newly secreted DIRFs) remained within a range of 1 to 10 according to the experiments mentioned above, DS V  and 1 DS K (i=1,2) were set to 100 and 10, respectively, as the concentration of BRAF inhibitor changed from 0.1 to 1 in the simulation. Note that in
, the degradation rate ( Therefore, to reproduce this change in our simulation,  was set to 0.3, and 3_DIRF K was set to 0.01.

(intensity of Poisson process) in Equation (11) was scaled and estimated from Ref. [2] .
Parameters fitted to the clinical data. The clinical data of progression-free survival percentages ( Figure   1A in Ref. [6] ) were used to estimate parameters including d S (maximal inhibition rate of drug on drugsensitive cells), K Tm (Michaelis constant for maximal carrying capacity of drug-sensitive/resistant cells), M max (maximal carrying capacity of new metastatic cells) and  (diffusion coefficient in Wiener process).
The clinical data include progression-free survival percentages of a patient cohort treated with daily dosing of BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib administered for 21 days, followed by 7 days off. By iteratively calibration, we chose the values of the above parameters which produced good agreement with the clinical data (see Supplementary Fig. S1 ). It should be noted that another independent set of clinical data ( Figure 1A in Ref. [7] ) was used for validating our model predictions at patient population level, as presented in Fig. 3 in the main text.
Text S2. Sensitivity analysis
Sensitivity analysis was used to quantitatively explore the critical parameters in the model that affected cellular dynamics and survival percentage. A sensitivity coefficient [8] for total tumor cell number with respect to parameter j p was calculated as follows:
T , with L =360 and T =360 days in the simulation. The sensitivity coefficient of the survival percentage with respect to parameter j p was also calculated according to the following formula: 
Single-parameter sensitivity analysis
Each parameter was increased by 50% from its estimated value and we then obtained the relative changes in area under curve of total tumor cell number and area under survival curve, as defined by equations (S1-S2). The computations were repeated 20 times, and the mean value and standard deviation of the sensitivity coefficients were calculated.
Two-parameter sensitivity analysis
To assess the combinatorial effects of parameters involved in the model, we performed a two- Remarks: "_" in the above Table S1 represents dimensionless unit.
